Edwards Lifesciences (EW) Gains from Investment Securities (2009 - 2026)

Edwards Lifesciences' Gains from Investment Securities history runs 18 years deep, the most recent figure standing at -$500000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 86.11% year-over-year to -$500000.0; the TTM figure through Mar 2026 stood at -$25.6 million (down 57.06% YoY), while the FY2024 annual figure was -$13.2 million, down 55.29% from the prior year.
• Gains from Investment Securities was -$500000.0 for Q1 2026 at Edwards Lifesciences, up from -$7.9 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $17.7 million in Q4 2023 to a low of -$58.7 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged -$11.6 million across 5 years, with a median of -$10.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities tumbled 1236.36% in 2022, then surged 130.15% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$58.7 million in 2022, then soared by 130.15% to $17.7 million in 2023, then sank by 171.75% to -$12.7 million in 2024, then surged by 37.8% to -$7.9 million in 2025, then soared by 93.67% to -$500000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$500000.0 (Q1 2026), -$7.9 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.